Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ --

- Study Triggers $7.5m Milestones for Both Companies

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The study has now appeared on clinicaltrials.gov and will be recruiting in the next few weeks when the first patient first visit will trigger a $7.5 million milestone payment to both Sosei and Vectura.

The trial is a randomised, double-blind, placebo-controlled, parallel-group design, including an open-label tiotropium bromide arm, and will assess efficacy, safety and tolerability of NVA237 in patients with COPD. It will include approximately 1000 patients with moderate to severe COPD from study centres across the USA, Europe and other territories. Each patient will be randomised to receive a once-daily dose of placebo, tiotropium bromide or 50microg of NVA237 for a 52-week period. The primary endpoint of the study will be the change from baseline in FEV1 (forced expiratory volume in one second) over 12 weeks of treatment. A number of secondary endpoints will also be evaluated.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Novartis intends to launch NVA237 as a once-daily monotherapy for COPD and also in combination with Novartis' investigational once-daily, long-acting beta2-agonist (LABA) indacaterol (QAB149), which was filed for approval with the regulatory authorities as a monotherapy treatment for COPD at the end of 2008. The combination of NVA237 and indacaterol is known as QVA149. NDA submissions
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... Mass. and JERUSALEM, Israel, Aug. 31, 2015 /PRNewswire/ ... late-stage biopharmaceutical company developing octreotide capsules for the ... the second quarter ended June 30, 2015 and ... few months have been a transformative time for ... offering and recently announced that our first New ...
(Date:8/31/2015)... Thousands of people will peacefully demonstrate their frustration with ... at dozens of rallies across the country today. Since ... United States has experienced skyrocketing rates of ... yet the President has never once spoken publicly about ... President Obama , rally organizers compared his failure to ...
Breaking Medicine Technology:DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
... Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced that company ... in March. Citi 2011 Global Healthcare Conference ... Tuesday March 1, 2011 Presentation time: 8:00am ET ... Location: Boston Marriott, Boston, MA Presentation date: Tuesday March ...
Cached Medicine Technology:Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:9/1/2015)... , ... September 01, 2015 , ... ... monitoring and analysis of pet vital signs and activity, today announced its integration ... of the most popular and widely-adopted veterinary hospital Practice Management Software packages in ...
(Date:9/1/2015)... ... , ... Zecurion, a leading developer of data loss prevention solutions, announced the ... developed specifically for Mac OS. , In June 2015, the company successfully completed the ... professionals had participated. The beta test done by the developer community enabled Zecurion to ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... SC&H Group, ... (IPA), which includes being named a “Best of the Best” firm in the U.S., ... has named the “Best of the Best” in the U.S., selected exclusively on performance ...
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm ... investor-families have received permanent green cards (I-829 petition approval) from the USCIS through ... is the final step of the EB-5 visa process for immigrant investors to ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
Breaking Medicine News(10 mins):Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3
... www.mobilemassageteam.com ), a leading provider of on-site seated ... affairs, today announced that the company will be a sponsor ... ( http://www.globalfit.com/summit/ ) held on Thursday, ... City Philadelphia. Team members will be set up on ...
... Fight Against Tobacco Recognized Nationally -WASHINGTON, May 6 ... has been named the National Youth Advocate of the Year ... the fight against tobacco. Emily is being honored at a ... regional winners and a group winner. (Logo: ...
... released today by Ernst Berndt and Mark Trusheim of ... that eliminating FDA,s preemption protection would decrease patients, access ... reduce medical device industry employment. The paper, ... Devices on Patients, Innovation and Jobs," comes as ...
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that Brian S. Moore, ... Vice President and Chief Financial Officer, are scheduled to present ... Conference at the Palace Hotel in New York City on ...
... Performance athletes need to know their blood lactate level. ... their blood as a result of physical exertion and ... athletes therefore regularly have to attend performance diagnosis sessions. ... of exertion, a doctor takes blood samples from an ...
... May 6 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) (,BMP ... , -- Oppenheimer 3rd Annual China Dragon Call Conference, ... Madison Avenue in New York City. Management is currently, ... at 8:30, am ET on Tuesday, ...
Cached Medicine News:Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Removing Medical Device Preemption Impacts Jobs, Health Care Costs, Patient Access 2Health News:Symmetry Medical to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference 2Health News:Lactate test made easy 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: